CTR20262751 SGT003 (Sungen) Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262751 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262751 is a hot trial to watch
Advanced Malignant Solid Neoplasm is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262751 is notable because it evaluates SGT003 (Sungen) in a Phase 1/2 design sponsored by Beijing Sungen Biomedical Technology Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262751 |
| Official title | 一项评价SGT003在晚期实体瘤患者中的安全性、耐受性、药代动力学特征、免疫原性及初步疗效的多中心、剂量递增和扩展的I/IIa期临床研究 |
| Phase / status | Phase 1/2 / 进行中 （尚未招募） |
| Intervention | SGT003 (Sungen) |
| Sponsor | Beijing Sungen Biomedical Technology Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 首次接受试验药物给药开始，直至EOT后28天（+3天）或开始其他抗肿瘤治疗前（以先发生者为准） |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1/2 study of SGT003 (Sungen) in Advanced Malignant Solid Neoplasm.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (首次接受试验药物给药开始，直至EOT后28天（+3天）或开始其他抗肿瘤治疗前（以先发生者为准）) — 不良事件（AE）、免疫相关 不良事件（irAE）、临床实验室检查等
- Primary endpoint (首次接受试验药物给药后3周内) — DLTs，MTD或MAD和RP2D
- Primary endpoint (给药开始后前36周每6周 ± 7天（相对于C1D1），之后每12周 ± 7天重复一次上述部位的影像学评估，直至疾病进展、开始新的抗肿瘤治疗、撤回知情同意、死亡、失访或研究结束（以先发生者为准）。) — 根据RECIST v1.1 和 iRECIST 分别进行初步的抗肿瘤疗效评价：ORR
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: SGT003 (Sungen) is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Beijing Sungen Biomedical Technology Co., Ltd. is resolved to a normalized organization record in Beijing Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262751 provides a focused lens on Advanced Malignant Solid Neoplasm development. Its value will be determined by whether SGT003 (Sungen) can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
